Haleon PLC Drives Share Gains With Evidence‑Based Heart Health Supplements
Haleon PLC’s steady rise in a booming cardiovascular‑health supplement market: evidence‑based trials, regulatory alignment, and investor upside.
4 minutes to read
Dr. Michael Chen
Biotech Science Reporter
Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.
AI Author, more information here
Otsuka Holdings Beats FY2025 Targets, Projects Modest FY2026 Outlook
Otsuka Holdings reports 2025 revenue & profit growth, a 140‑yen dividend, and Phase III success for its IL‑23 psoriasis drug, while forecasting modest 2026 results.
4 minutes to read
Alnylam Posts Record Q4 2025 Profit, 100% Revenue Surge, Eyes Strong 2026 Growth
Alnylam’s Q4 2025 results turn a loss into a $45 M profit, fueled by $1.78 B in product revenue from its first‑in‑class ASO and siRNA therapies, and a 2026 outlook of $3.4‑$3.8 B in growth.
4 minutes to read
Regeneron’s Feb‑2026 Investor Webcast Highlights ADC, BiTE and PI3K Therapies
Regeneron’s February 2026 investor webcast reveals breakthrough ADC and BiTE oncology therapies, promising 45‑70% response rates and accelerated FDA approvals.
- Regeneron Pharmaceuticals Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
4 minutes to read
Vertex Pharma Q4 2025 Earnings Beat Expectations, Projects 2026 Revenue Above $12 B
Vertex Pharmaceuticals reports Q4 2025 revenue up 11.3% to $1.54B and 2026 guidance for mid‑$12B, driven by CF sales and new non‑CF orphan‑designated therapies.
4 minutes to read
WuXi AppTec Shares Surge as Analysts Raise Forecasts and Target‑Price
WuXi AppTec shares surge after Nomura lifts target to HK$157, driven by a strong chemical‑business outlook and expanding biopharma service portfolio.
3 minutes to read
Zoetis Q4 2025 Beats Estimates, Eyes Strong FY 2026 Growth Amid Biologics Push
Zoetis beats Q4 2025 earnings, tops revenue and EPS forecasts, and ramps up biologics and companion‑animal vaccines, boosting FY‑2026 outlook.
4 minutes to read
IQVIA Earnings Outlook: Analyst Buzz, Growth Signals and Cautious Targets
IQVIA Holdings’ analyst buzz: bullish growth‑fund buy, mixed bank targets, and a data‑science edge that investors eye for next‑quarter earnings.
3 minutes to read
Hikma Shares Dip Amid Market Pullback, Still Strong Pharma Outlook
Hikma Pharmaceuticals PLC’s share dip reflects market pullback, not fundamentals. Dual specialty‑drug and generic strategy keeps long‑term value stable.
4 minutes to read
Incyte’s Analyst Upside: Strong Pipeline, Breakthroughs & Boosted Target Prices
Incyte’s upgraded analyst outlook highlights strong small‑molecule oncology pipeline, clinical success in KRAS G12C and NTRK tumors, and fast‑track approvals driving near‑term growth.
5 minutes to read